2170 — Suzhou Basecare Medical Share Price
0.000.00%
Last trade - 00:00- HK$875.28m
- HK$492.05m
- CNY299.11m
- 18
- 28
- 90
- 41
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 143.48 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.72 | ||
| Price to Tang. Book | 0.91 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.75 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -15.66% | ||
| Return on Equity | -18.65% | ||
| Operating Margin | -77.22% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 81.11 | 107.3 | 140.9 | 207.98 | 299.11 | 518.21 | 634.08 | 39.96% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Suzhou Basecare Medical Corp Ltd, formerly Jiangsu Double Helix Biology Science and Technology Co Ltd, is a China-based investment holding company mainly engaged in the provision of assisted reproductive genetic testing solutions. The Company provides genetic testing solutions and sells genetic testing equipment and instruments. The genetic testing solutions include sales of testing kits and provision of testing services. The Company's main products include PGT-A kits. The Company mainly conducts business within the domestic market.
Directors
- Bo Liang CHM (40)
- Bing Huang CSU (28)
- Jing Dai CFO (33)
- Maoshe Rui COO (32)
- Lingyin Kong CTO (40)
- Lok Kwan Yim SEC
- Weipeng Wang NED (32)
- Wenbo Xu NED (36)
- Jiecheng Zhang NED (31)
- Kwok Keung Chau NID
- Taosheng Huang NID (59)
- Xixiong Kang NID (68)
- Yi Lin SUB (51)
- Tingting Zhu SUB (27)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 14th, 2010
- Public Since
- February 8th, 2021
- No. of Employees
- 497
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 273,526,000
- Address
- Unit 101, Building A3, BioBay, SUZHOU, 215400
- Web
- https://www.basecare.cn/
- Phone
- +86 51282782588
- Auditors
- KPMG
Upcoming Events for 2170
Suzhou Basecare Medical Corp Ltd Annual Shareholders Meeting
Similar to 2170
Adicon Holdings
Stock Exchange of Hong Kong Limited
Aidigong Maternal & Child Health
Stock Exchange of Hong Kong Limited
Arrail
Stock Exchange of Hong Kong Limited
Beijing Health (Holdings)
Stock Exchange of Hong Kong Limited
Chaoju Eye Care Holdings
Stock Exchange of Hong Kong Limited
FAQ
What is the Suzhou Basecare Medical share price?
As of Today at 19:30 UTC, shares in Suzhou Basecare Medical are trading at HK$3.20. This share price information is delayed by 15 minutes.
How has the Suzhou Basecare Medical share price performed this year?
Shares in Suzhou Basecare Medical last closed at HK$3.20 and the price had moved by +60% over the past 365 days. In terms of relative price strength the Suzhou Basecare Medical share price has outperformed the FTSE Developed Asia Pacific Index by +61.83% over the past year.
What are the analyst and broker recommendations for Suzhou Basecare Medical?
The overall consensus recommendation for Suzhou Basecare Medical is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Suzhou Basecare Medical dividend yield?
Suzhou Basecare Medical does not currently pay a dividend.
Does Suzhou Basecare Medical pay a dividend?
Suzhou Basecare Medical does not currently pay a dividend.
When does Suzhou Basecare Medical next pay dividends?
Suzhou Basecare Medical does not currently pay a dividend.
How do I buy Suzhou Basecare Medical shares?
To buy shares in Suzhou Basecare Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Suzhou Basecare Medical?
As of the previous close price of HK$3.20, shares in Suzhou Basecare Medical had a market capitalisation of HK$875.28m.
Where are Suzhou Basecare Medical shares listed?
Here are the trading details for Suzhou Basecare Medical:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2170
What kind of share is Suzhou Basecare Medical?
Based on an overall assessment of its quality, value and momentum Suzhou Basecare Medical is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Suzhou Basecare Medical share price forecast for 2025?
The analyst consensus target price for shares in Suzhou Basecare Medical is HK$10.00. That is 212.53% above the last closing price of HK$3.20.
Analysts covering Suzhou Basecare Medical currently have a consensus Earnings Per Share (EPS) forecast of -CNY0.07 for the next financial year.
Find out moreWhat is the trend in the Suzhou Basecare Medical share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Suzhou Basecare Medical. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +18.56%.
As of the last closing price of HK$3.20, shares in Suzhou Basecare Medical were trading +23.77% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Suzhou Basecare Medical PE Ratio?
The Suzhou Basecare Medical PE ratio based on its reported earnings over the past 12 months is 143.48. The shares last closed at HK$3.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Suzhou Basecare Medical?
Suzhou Basecare Medical's management team is headed by:
- Bo Liang - CHM
- Bing Huang - CSU
- Jing Dai - CFO
- Maoshe Rui - COO
- Lingyin Kong - CTO
- Lok Kwan Yim - SEC
- Weipeng Wang - NED
- Wenbo Xu - NED
- Jiecheng Zhang - NED
- Kwok Keung Chau - NID
- Taosheng Huang - NID
- Xixiong Kang - NID
- Yi Lin - SUB
- Tingting Zhu - SUB